Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein
View Patent ↗The present application describes RGM A binding proteins, particularly monoclonal antibodies, and in particular CDR grafted, humanized versions thereof, which have the ability to bind to RGM A and prevent binding of RGM proteins to RGM A receptor and other RGM A binding proteins, and therefore neutralize the function of RGM A, for use in the treatment of retinal nerve fiber layer (RNFL) degeneration as well as methods of therapeutically or prophylactically treating a mammal against RNFL degeneration.
1. A method of treating retinal nerve fiber layer (RNFL) degeneration, comprising the step of administering to a mammal in need thereof an effective amount of a composition comprising an isolated antibody, wherein the isolated antibody comprises an antigen binding domain, said antibody capable of binding an epitope of a retinal guidance molecule (RGM), said antigen binding domain comprising a heavy chain variable domain having three complementary determining regions and a light chain variable domain having three complementary determining regions, wherein the three complementary determining regions of the heavy chain variable domain have the amino acid sequence of SEQ ID NO:57, SEQ ID NO:58 and SEQ ID NO:59 and the three complementary determining regions of the light chain variable domain have the amino acid sequence of SEQ ID NO:60, SEQ ID NO:61 and SEQ ID NO:62.
2. The method of claim 1 , wherein said treatment is an therapeutic, neuroregenerative or neuroprotective, local or systemic treatment.
3. The method of claim 1 , wherein the antibody is a monoclonal antibody, a chimeric antibody or a humanized antibody.
4. The method of claim 1 , wherein said antibody further comprises a human acceptor framework, and wherein said human acceptor framework comprises at least one amino acid sequence selected from the group consisting of: SEQ ID NO: 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32 and 33.
5. The method of claim 4 , wherein the antibody is a monoclonal antibody, a chimeric antibody or a humanized antibody.
6. A method of treating retinal nerve fiber layer (RNFL) degeneration, comprising the step of administering to a mammal in need thereof an effective amount of a composition comprising an isolated antibody,
wherein the isolated antibody comprises an antigen binding domain, said antibody capable of binding an epitope of a retinal guidance molecule (RGM), said antigen binding domain comprising a heavy chain variable domain and a light chain variable domain selected from the group consisting of:
(a) the heavy chain variable domain having the amino acid sequence of SEQ ID NO:47 and the light chain variable domain having the amino acid sequence of SEQ ID NO:44,
(b) heavy chain variable domain having the amino acid sequence of SEQ ID NO:48 and the light chain variable domain having the amino acid sequence of SEQ ID NO:44,
(c) the heavy chain variable domain having the amino acid sequence of SEQ ID NO:49 and the light chain variable domain having the amino acid sequence of SEQ ID NO:44,
(d) the heavy chain variable domain having the amino acid sequence of SEQ ID NO:50 and the light chain variable domain having the amino acid sequence of SEQ ID NO:44,
(e) the heavy chain variable domain having the amino acid sequence of SEQ ID NO:47 and the light chain variable domain having the amino acid sequence of SEQ ID NO:45,
(f) the heavy chain variable domain having the amino acid sequence of SEQ ID NO:48 and the light chain variable domain having the amino acid sequence of SEQ ID NO:45,
(g) the heavy chain variable domain having the amino acid sequence of SEQ ID NO:49 and the light chain variable domain having the amino acid sequence of SEQ ID NO:45,
(h) the heavy chain variable domain having the amino acid sequence of SEQ ID NO:50 and the light chain variable domain having the amino acid sequence of SEQ ID NO:45,
(i) the heavy chain variable domain having the amino acid sequence of SEQ ID NO:47 and the light chain variable domain having the amino acid sequence of SEQ ID NO:46,
(j) the heavy chain variable domain having the amino acid sequence of SEQ ID NO:48 and the light chain variable domain having the amino acid sequence of SEQ ID NO:46,
(k) the heavy chain variable domain having the amino acid sequence of SEQ ID NO:49 and the light chain variable domain having the amino acid sequence of SEQ ID NO:46,
(l) the heavy chain variable domain having the amino acid sequence of SEQ ID NO:50 and the light chain variable domain having the amino acid sequence of SEQ ID NO:46,
(m) the heavy chain variable domain having the amino acid sequence of SEQ ID NO:48 and the light chain variable domain having the amino acid sequence of SEQ ID NO:51,
(n) the heavy chain variable domain having the amino acid sequence of SEQ ID NO:48 and the light chain variable domain having the amino acid sequence of SEQ ID NO:52,
(o) the heavy chain variable domain having the amino acid sequence of SEQ ID NO:48 and the light chain variable domain having the amino acid sequence of SEQ ID NO:53,
(p) the heavy chain variable domain having the amino acid sequence of SEQ ID NO:48 and the light chain variable domain having the amino acid sequence of SEQ ID NO:54,
(q) the heavy chain variable domain having the amino acid sequence of SEQ ID NO:50 and the light chain variable domain having the amino acid sequence of SEQ ID NO:51,
(r) the heavy chain variable domain having the amino acid sequence of SEQ ID NO:50 and the light chain variable domain having the amino acid sequence of SEQ ID NO:52,
(s) the heavy chain variable domain having the amino acid sequence of SEQ ID NO:50 and the light chain variable domain having the amino acid sequence of SEQ ID NO:53, and
(t) the heavy chain variable domain having the amino acid sequence of SEQ ID NO:50 and the light chain variable domain having the amino acid sequence of SEQ ID NO:54.
7. The method of claim 6 , wherein said treatment is an therapeutic, neuroregenerative or neuroprotective, local or systemic treatment.
8. The method of claim 6 , wherein the antibody is a monoclonal antibody, a chimeric antibody or a humanized antibody.